Calcium channel blockers reverse muscle weakness in animal model of myotonic dystrophy type 1

New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these symptoms in animal models of the disease.

RvT4 molecule boosts the body’s defenses against atherosclerosis in rheumatoid arthritis patients

Researchers from Queen Mary University of London have found that the molecule RvT4 enhances the body’s natural defences against atherosclerosis (hardening of the arteries) in

February 6, 2024

Enlivex’s shares cut in half after ‘biases’ cloud Ph2 cell therapy data in sepsis

Enlivex Therapeutics’ cell therapy has disappointed investors because its impact in a mid-stage test in sepsis was difficult to figure out. The company nonetheless said

April 13, 2024

Exclusive: Backed by MIT’s Andrew Lo, Quantile Health raises $6M to bolster gene therapy access

In a bid to overcome some of the commercial challenges faced by expensive new gene therapies, Quantile Health has raised $6 million for a financial

March 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.